Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Endocrinology, Chongqing University Fuling Hospital, Chongqing, China.
Aging Clin Exp Res. 2023 Sep;35(9):1917-1926. doi: 10.1007/s40520-023-02473-0. Epub 2023 Jun 22.
This study aimed to compare the prevalence of sarcopenia according to the old and new Asian Working Group on Sarcopenia (AWGS) operational criteria and explore the effects of sarcopenia on adverse outcomes in older adults with type 2 diabetes (T2D).
A total of 386 patients with T2D aged ≥ 60 years were recruited in retrospective cohort study. Sarcopenia was assessed with different versions of the AWGS consensus, including the AWGS2014, AWGS2019H (muscle mass adjusted for height), and AWGS2019B (muscle mass adjusted for body mass index). The median follow-up period was 47 months. The composite primary endpoint was the first occurrence of cardiovascular disease (CVD), fragility fracture, and all-cause mortality and the secondary outcomes included the three separate components of the primary outcome.
In this study, the prevalence of sarcopenia under different criteria was significantly different, with AWGS2019H having the highest prevalence of 31.3%. The agreement among sarcopenia criteria was unsatisfactory. By Cox regression analysis, all three AWGS definitions of sarcopenia were associated with the composite outcome of all-cause mortality, fracture and CVD (hazard ratio [HR], 2.69 vs. HR, 2.63; vs. HR, 2.23; model 3). Further exploratory analysis, sarcopenia defined by the AWGS2019H criteria was an independent risk factor for death, incident CVD, and fractures. While AWGS2014 criteria was an increased risk factor of death and CVD. The AWGS2019B criteria were only associated with incident fractures.
All three AWGS definitions of sarcopenia were associated the composite primary endpoint. Additionally, the AWGS2019H criteria may be a better independent risk factor for negative health outcomes.
本研究旨在比较根据旧版和新版亚洲肌少症工作组(AWGS)操作标准定义的肌少症患病率,并探讨肌少症对老年 2 型糖尿病(T2D)患者不良结局的影响。
本回顾性队列研究共纳入 386 例年龄≥60 岁的 T2D 患者。使用不同版本的 AWGS 共识,包括 AWGS2014、AWGS2019H(按身高调整的肌肉质量)和 AWGS2019B(按体重指数调整的肌肉质量)来评估肌少症。中位随访时间为 47 个月。复合主要终点为心血管疾病(CVD)、脆性骨折和全因死亡率的首次发生,次要终点包括主要结局的三个单独组成部分。
在本研究中,不同标准下肌少症的患病率差异显著,AWGS2019H 的患病率最高,为 31.3%。肌少症标准之间的一致性不理想。通过 Cox 回归分析,所有三种 AWGS 肌少症定义均与全因死亡率、骨折和 CVD 的复合结局相关(风险比[HR],2.69;HR,2.63;HR,2.23;模型 3)。进一步的探索性分析表明,AWGS2019H 标准定义的肌少症是死亡、新发 CVD 和骨折的独立危险因素。而 AWGS2014 标准是死亡和 CVD 的危险因素增加。AWGS2019B 标准仅与新发骨折相关。
所有三种 AWGS 肌少症定义均与复合主要终点相关。此外,AWGS2019H 标准可能是不良健康结局的更好独立危险因素。